Methylergonovine Maleate
10 NDCs across 6 manufacturers|8 Generic,2 Brand
Methylergonovine Maleate is used to treat postpartum hemorrhage, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Nov 24, 2008. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $342K on Methylergonovine Maleate across 191 claims for 67 beneficiaries.
Methylergonovine Maleate is available as 10 NDCs from 6 manufacturers (8 generic, 2 brand), with NADAC prices from $4.50 to $59.64 per EA — the most expensive product costs about 13× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
10
8G / 2B
Manufacturers
6
competing in market
Price Spread
$4.50 – $59.64
per EA
7d Activity
avg +3.4% WoW · of 10 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Lupin Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Ergot Derivative class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing METHYLERGONOVINE MALEATE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
METHERGINE 0.2 MG TABLET | $59.6363 per EA | — |
METHERGINE 0.2 MG TABLET | $59.6363 per EA | — |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
METHYLERGONOVINE 0.2 MG TABLET | $4.4972 per EA | +3.37% |
Frequently Asked Questions
What is Methylergonovine Maleate used to treat?
Methylergonovine Maleate is used to treat postpartum hemorrhage, per the National Library of Medicine's MED-RT classification.
When did Methylergonovine Maleate become available as a generic?
FDA approved the first generic Methylergonovine Maleate (ANDA) on Nov 24, 2008. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Methylergonovine Maleate?
In 2024, Medicare Part D spent $342K on Methylergonovine Maleate across 191 claims for 67 beneficiaries.
How many Methylergonovine Maleate products are on the market?
The Methylergonovine Maleate drug market contains 10 NDCs from 6 manufacturers — 8 generic and 2 brand products.
What is the price range for Methylergonovine Maleate?
NADAC reference prices for Methylergonovine Maleate range from $4.4972 to $59.6363 per EA — the most expensive product costs about 13× the cheapest.
Is generic Methylergonovine Maleate cheaper than brand?
The average generic NADAC for Methylergonovine Maleate is $4.4972 per EA, versus $59.6363 for brand-labeled products — brand versions average about 13× the generic price.
Which manufacturers make Methylergonovine Maleate?
6 manufacturers list Methylergonovine Maleate in NADAC. Ranked by number of NDCs, the largest are Lupin Pharmaceuticals Inc. (2), Rising Pharma Holdings Inc. (2), Teva Pharmaceuticals USA Inc. (2), Granules Pharmaceuticals Inc. (2), Major Pharmaceuticals (1).
How has the price of Methylergonovine Maleate changed recently?
Over the past 7 days, 8 Methylergonovine Maleate NDCs rose and 0 fell, with a market-wide average change of +3.4%.